Quetiapine for the continuation treatment of bipolar depression: Naturalistic prospective case series from the Stanley Bipolar Treatment Network

Trisha Suppes, Dorothy I. Kelly, Paul E. Keck, Susan L. McElroy, Lori L. Altshuler, Jim Mintz, Mark A Frye, Willem A. Nolen, David A. Luckenbaugh, Robert M. Post, Gabriele S. Leverich, Ralph W. Kupka, Heinz Grunze

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Continuation treatment for bipolar disorder often consists of a mood stabilizer and a second-generation antipsychotic. Quetiapine has been shown to be an effective treatment for acute mania and acute bipolar depression, but there are limited data for its use in continuation treatment. This study examined the effectiveness of open-label adjunctive quetiapine therapy for continuation treatment in patients with bipolar disorder.Prospectively collected life chart data from 63 outpatients with bipolar disorders, most recent episodes depressed, manic, or cycling, who received adjunctive quetiapine therapy as part of standard acute treatment were analyzed. Patients had 4 or more weeks of prequetiapine baseline data and at least 2 weeks of quetiapine treatment with no other medication changes. Patients were grouped by baseline symptoms; depression only, mania only, or both mania and depression (cycling group). Owing to small mania and well groups (n=4), differences between depression and cycling groups were examined and mania and well groups excluded. Fifty-five patients were included in the analyses. The primary outcome measure was change in mood severity from baseline to change in treatment regimen, as measured by the NIMH Life Charting Method.Patients received adjunctive quetiapine for a mean of 122 (SD=149) days. Both groups showed significant improvement in depression ratings and time spent depressed by week 10. Both groups showed significant improvement in overall mood. No between-group differences in improvement were found.Adjunctive quetiapine may be useful as continuation treatment in bipolar populations with both pure depressive and cycling symptoms. Further controlled studies are warranted.

Original languageEnglish (US)
Pages (from-to)376-381
Number of pages6
JournalInternational Clinical Psychopharmacology
Volume22
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Bipolar Disorder
Depression
Therapeutics
Quetiapine Fumarate
National Institute of Mental Health (U.S.)
Antipsychotic Agents
Outpatients
Outcome Assessment (Health Care)

Keywords

  • Bipolar depression
  • Bipolar disorder
  • Cycling
  • Quetiapine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Quetiapine for the continuation treatment of bipolar depression : Naturalistic prospective case series from the Stanley Bipolar Treatment Network. / Suppes, Trisha; Kelly, Dorothy I.; Keck, Paul E.; McElroy, Susan L.; Altshuler, Lori L.; Mintz, Jim; Frye, Mark A; Nolen, Willem A.; Luckenbaugh, David A.; Post, Robert M.; Leverich, Gabriele S.; Kupka, Ralph W.; Grunze, Heinz.

In: International Clinical Psychopharmacology, Vol. 22, No. 6, 11.2007, p. 376-381.

Research output: Contribution to journalArticle

Suppes, T, Kelly, DI, Keck, PE, McElroy, SL, Altshuler, LL, Mintz, J, Frye, MA, Nolen, WA, Luckenbaugh, DA, Post, RM, Leverich, GS, Kupka, RW & Grunze, H 2007, 'Quetiapine for the continuation treatment of bipolar depression: Naturalistic prospective case series from the Stanley Bipolar Treatment Network', International Clinical Psychopharmacology, vol. 22, no. 6, pp. 376-381. https://doi.org/10.1097/YIC.0b013e3281c55f63
Suppes, Trisha ; Kelly, Dorothy I. ; Keck, Paul E. ; McElroy, Susan L. ; Altshuler, Lori L. ; Mintz, Jim ; Frye, Mark A ; Nolen, Willem A. ; Luckenbaugh, David A. ; Post, Robert M. ; Leverich, Gabriele S. ; Kupka, Ralph W. ; Grunze, Heinz. / Quetiapine for the continuation treatment of bipolar depression : Naturalistic prospective case series from the Stanley Bipolar Treatment Network. In: International Clinical Psychopharmacology. 2007 ; Vol. 22, No. 6. pp. 376-381.
@article{8e09e69f8863483eb96121eb12b9cb93,
title = "Quetiapine for the continuation treatment of bipolar depression: Naturalistic prospective case series from the Stanley Bipolar Treatment Network",
abstract = "Continuation treatment for bipolar disorder often consists of a mood stabilizer and a second-generation antipsychotic. Quetiapine has been shown to be an effective treatment for acute mania and acute bipolar depression, but there are limited data for its use in continuation treatment. This study examined the effectiveness of open-label adjunctive quetiapine therapy for continuation treatment in patients with bipolar disorder.Prospectively collected life chart data from 63 outpatients with bipolar disorders, most recent episodes depressed, manic, or cycling, who received adjunctive quetiapine therapy as part of standard acute treatment were analyzed. Patients had 4 or more weeks of prequetiapine baseline data and at least 2 weeks of quetiapine treatment with no other medication changes. Patients were grouped by baseline symptoms; depression only, mania only, or both mania and depression (cycling group). Owing to small mania and well groups (n=4), differences between depression and cycling groups were examined and mania and well groups excluded. Fifty-five patients were included in the analyses. The primary outcome measure was change in mood severity from baseline to change in treatment regimen, as measured by the NIMH Life Charting Method.Patients received adjunctive quetiapine for a mean of 122 (SD=149) days. Both groups showed significant improvement in depression ratings and time spent depressed by week 10. Both groups showed significant improvement in overall mood. No between-group differences in improvement were found.Adjunctive quetiapine may be useful as continuation treatment in bipolar populations with both pure depressive and cycling symptoms. Further controlled studies are warranted.",
keywords = "Bipolar depression, Bipolar disorder, Cycling, Quetiapine",
author = "Trisha Suppes and Kelly, {Dorothy I.} and Keck, {Paul E.} and McElroy, {Susan L.} and Altshuler, {Lori L.} and Jim Mintz and Frye, {Mark A} and Nolen, {Willem A.} and Luckenbaugh, {David A.} and Post, {Robert M.} and Leverich, {Gabriele S.} and Kupka, {Ralph W.} and Heinz Grunze",
year = "2007",
month = "11",
doi = "10.1097/YIC.0b013e3281c55f63",
language = "English (US)",
volume = "22",
pages = "376--381",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Quetiapine for the continuation treatment of bipolar depression

T2 - Naturalistic prospective case series from the Stanley Bipolar Treatment Network

AU - Suppes, Trisha

AU - Kelly, Dorothy I.

AU - Keck, Paul E.

AU - McElroy, Susan L.

AU - Altshuler, Lori L.

AU - Mintz, Jim

AU - Frye, Mark A

AU - Nolen, Willem A.

AU - Luckenbaugh, David A.

AU - Post, Robert M.

AU - Leverich, Gabriele S.

AU - Kupka, Ralph W.

AU - Grunze, Heinz

PY - 2007/11

Y1 - 2007/11

N2 - Continuation treatment for bipolar disorder often consists of a mood stabilizer and a second-generation antipsychotic. Quetiapine has been shown to be an effective treatment for acute mania and acute bipolar depression, but there are limited data for its use in continuation treatment. This study examined the effectiveness of open-label adjunctive quetiapine therapy for continuation treatment in patients with bipolar disorder.Prospectively collected life chart data from 63 outpatients with bipolar disorders, most recent episodes depressed, manic, or cycling, who received adjunctive quetiapine therapy as part of standard acute treatment were analyzed. Patients had 4 or more weeks of prequetiapine baseline data and at least 2 weeks of quetiapine treatment with no other medication changes. Patients were grouped by baseline symptoms; depression only, mania only, or both mania and depression (cycling group). Owing to small mania and well groups (n=4), differences between depression and cycling groups were examined and mania and well groups excluded. Fifty-five patients were included in the analyses. The primary outcome measure was change in mood severity from baseline to change in treatment regimen, as measured by the NIMH Life Charting Method.Patients received adjunctive quetiapine for a mean of 122 (SD=149) days. Both groups showed significant improvement in depression ratings and time spent depressed by week 10. Both groups showed significant improvement in overall mood. No between-group differences in improvement were found.Adjunctive quetiapine may be useful as continuation treatment in bipolar populations with both pure depressive and cycling symptoms. Further controlled studies are warranted.

AB - Continuation treatment for bipolar disorder often consists of a mood stabilizer and a second-generation antipsychotic. Quetiapine has been shown to be an effective treatment for acute mania and acute bipolar depression, but there are limited data for its use in continuation treatment. This study examined the effectiveness of open-label adjunctive quetiapine therapy for continuation treatment in patients with bipolar disorder.Prospectively collected life chart data from 63 outpatients with bipolar disorders, most recent episodes depressed, manic, or cycling, who received adjunctive quetiapine therapy as part of standard acute treatment were analyzed. Patients had 4 or more weeks of prequetiapine baseline data and at least 2 weeks of quetiapine treatment with no other medication changes. Patients were grouped by baseline symptoms; depression only, mania only, or both mania and depression (cycling group). Owing to small mania and well groups (n=4), differences between depression and cycling groups were examined and mania and well groups excluded. Fifty-five patients were included in the analyses. The primary outcome measure was change in mood severity from baseline to change in treatment regimen, as measured by the NIMH Life Charting Method.Patients received adjunctive quetiapine for a mean of 122 (SD=149) days. Both groups showed significant improvement in depression ratings and time spent depressed by week 10. Both groups showed significant improvement in overall mood. No between-group differences in improvement were found.Adjunctive quetiapine may be useful as continuation treatment in bipolar populations with both pure depressive and cycling symptoms. Further controlled studies are warranted.

KW - Bipolar depression

KW - Bipolar disorder

KW - Cycling

KW - Quetiapine

UR - http://www.scopus.com/inward/record.url?scp=34948860033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948860033&partnerID=8YFLogxK

U2 - 10.1097/YIC.0b013e3281c55f63

DO - 10.1097/YIC.0b013e3281c55f63

M3 - Article

C2 - 17917557

AN - SCOPUS:34948860033

VL - 22

SP - 376

EP - 381

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 6

ER -